RUNX3 promoter hypermethylation and prognosis of early surgically resected non-small cell lung cancers

Journal of Central South University (Medical Sciences)

Volumn 36, Issue 7, 2011, Pages 650-654

  Tang, Yan ^a,b   Wu, Fang ^a   Hu, Chunhong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Department of Oncology   (China)

Author keywords

DNA methylation; Epigenomics; Non small cell lung cancer; Prognosis; RUNX3 gene

Indexed keywords

RUNX3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RUNX3;

AGED; ARTICLE; DNA METHYLATION; FEMALE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; TIME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA METHYLATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; TIME FACTORS;

EID: 80052077717     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1672-7347.2011.07.012     Document Type: Article

References (18)

1. Anglim P P, Alonzo T A, Laird-Offringa I A, et al. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update [J]. Mol Cancer, 2008, 7:81.
2. Khandige S, Shanbhogue V V, Chakrabarty S, et al. Methylation markers: a potential force driving cancer diagnostics forward [J]. Oncol Res, 2011, 19(3/4):105-110.
3. Vidaver R M, Schachter B S. 2007 Annual Meeting of the National Lung Cancer Partnership; a summary of meeting highlights [J]. J Thorac Oncol, 2008, 3(2):190-193. (Pubitemid 351323197)
4. [4} Miyazono K, Suzuki H, Imamura T. Regulation of TGF-beta signaling and its roles in p regression of tumors [J]. Cancer Sci, 2003, 94(3):230-234. (Pubitemid 36575887)
5. Jiang Y, Tong D, Lou G, et al. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines [J]. Pathobiology, 2008, 75(4):244-251. (Pubitemid 351918429)
6. Kim E J, Kim Y J, Jeong P, et al. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor [J]. Urol, 2008, 180(3):1141-1145.
7. Nomoto S, Kinoshita T, Mori T, et al. Adverse prognosis of epigenetic inactivation in RUNX3 gene at lp36 in human pancreatic cancer [J]. Br J Cancer, 2008, 98(10):1690-1695. (Pubitemid 351684677)
8. Yanagawa N, Tamura G, Oizumi H, et al. Promoter hypermethylation of RASSF1A and KUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers [J]. Lung Cancer, 2007, 58(1):131-138. (Pubitemid 47379969)
9. Li QL, Kim H R, Kim W J, et al. Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer [J], Biochem Biophys Res Commun, 2004, 314(1):223-228.
10. Sato K, Tomizawa Y, Iijima H, et al. Epigenetic inactivation of the RUNX3 gene in lung cancer [J]. Oncol Rep, 2006, 15(1):129-135.
11. Yanagawa N, Tamura G, Oizumi H, et al. Promoter hypermethylation of tumor suppressor and tumor-related genes in nonsmall cell lung cancers [J]. Cancer Sci, 2003, 94(7):589-592. (Pubitemid 36975012)
12. Yanagawa N, Tamura G, Oizumi H, et al. Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: Relation with smoking status [J]. Anticancer Res, 2011, 31(4):1211-1214.
13. Araki K, Osaki M, Nagahama Y, et al. Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis [J], Cancer Sci, 2005, 96(4):227-231. (Pubitemid 40767060)
14. Inoue M, Minami M, Shiono H, et al. Clinicopathologic study of resected, peripheral, small-sized, non-small cell lung cancer tumors of 2 cm or less in diameter: pleural invasion and increase of serum carcinoembryonic antigen level as predictors of nodal involvement [J]. Thorac Cardiovasc Surg, 2006, 131(5):988-993.
15. Jones D R, Daniel T M, Denlinger C E, et al. Stage IB nonsmall cell lung cancers: are they all the same [J]. Ann Thorac Surg, 2006, 81(6):1958-1962. (Pubitemid 43775565)
16. Herranz M, Esteller M. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets [J]. Methods Mol Biol, 2007, 361:25-62. (Pubitemid 350183201)
17. Fojtova M, Piskala A, Votruba I, et al. Efficacy of DNA hypomethylating capacities of 5-aza-2'-deoxycytidine and its alpha anomer [J]. Pharmacol Res, 2007, 55(1):16-22. (Pubitemid 46108582)
18. Mack G S. Epigenetic cancer therapy makes headway [J]. Natl Cancer Inst, 2006, 98(20):1443-1444.